340 related articles for article (PubMed ID: 20484426)
1. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors.
Troost EG; Bussink J; Hoffmann AL; Boerman OC; Oyen WJ; Kaanders JH
J Nucl Med; 2010 Jun; 51(6):866-74. PubMed ID: 20484426
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?
Biehl KJ; Kong FM; Dehdashti F; Jin JY; Mutic S; El Naqa I; Siegel BA; Bradley JD
J Nucl Med; 2006 Nov; 47(11):1808-12. PubMed ID: 17079814
[TBL] [Abstract][Full Text] [Related]
3. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
[TBL] [Abstract][Full Text] [Related]
4. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL
J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
6. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes.
van Baardwijk A; Bosmans G; Boersma L; Buijsen J; Wanders S; Hochstenbag M; van Suylen RJ; Dekker A; Dehing-Oberije C; Houben R; Bentzen SM; van Kroonenburgh M; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):771-8. PubMed ID: 17398018
[TBL] [Abstract][Full Text] [Related]
7. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma.
Deantonio L; Beldì D; Gambaro G; Loi G; Brambilla M; Inglese E; Krengli M
Radiat Oncol; 2008 Sep; 3():29. PubMed ID: 18801181
[TBL] [Abstract][Full Text] [Related]
9. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
[TBL] [Abstract][Full Text] [Related]
10. Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation.
Castadot P; Geets X; Lee JA; Christian N; Grégoire V
Radiother Oncol; 2010 May; 95(2):209-17. PubMed ID: 20385413
[TBL] [Abstract][Full Text] [Related]
11. Dose-escalation using intensity-modulated radiotherapy for prostate cancer--evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost.
Pinkawa M; Attieh C; Piroth MD; Holy R; Nussen S; Klotz J; Hawickhorst R; Schäfer W; Eble MJ
Radiother Oncol; 2009 Nov; 93(2):213-9. PubMed ID: 19717197
[TBL] [Abstract][Full Text] [Related]
12. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG.
Tian J; Yang X; Yu L; Chen P; Xin J; Ma L; Feng H; Tan Y; Zhao Z; Wu W
J Nucl Med; 2008 Feb; 49(2):186-94. PubMed ID: 18199618
[TBL] [Abstract][Full Text] [Related]
13. Variation in radiotherapy target volume definition, dose to organs at risk and clinical target volumes using anatomic (computed tomography) versus combined anatomic and molecular imaging (positron emission tomography/computed tomography): intensity-modulated radiotherapy delivered using a tomotherapy Hi Art machine: final results of the VortigERN study.
Chatterjee S; Frew J; Mott J; McCallum H; Stevenson P; Maxwell R; Wilsdon J; Kelly CG
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e173-9. PubMed ID: 23079100
[TBL] [Abstract][Full Text] [Related]
14. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.
Idema AJ; Hoffmann AL; Boogaarts HD; Troost EG; Wesseling P; Heerschap A; van der Graaf WT; Grotenhuis JA; Oyen WJ
J Nucl Med; 2012 Dec; 53(12):1904-10. PubMed ID: 23077112
[TBL] [Abstract][Full Text] [Related]
15. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
[TBL] [Abstract][Full Text] [Related]
16. Gradient-based delineation of the primary GTV on FLT PET in squamous cell cancer of the thoracic esophagus and impact on radiotherapy planning.
Zhang G; Han D; Ma C; Lu J; Sun T; Liu T; Zhu J; Zhou J; Yin Y
Radiat Oncol; 2015 Jan; 10():11. PubMed ID: 25572431
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma.
Inubushi M; Saga T; Koizumi M; Takagi R; Hasegawa A; Koto M; Wakatuki M; Morikawa T; Yoshikawa K; Tanimoto K; Fukumura T; Yamada S; Kamada T
Ann Nucl Med; 2013 Jan; 27(1):1-10. PubMed ID: 22914968
[TBL] [Abstract][Full Text] [Related]
18. PET/CT with 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors?
Pfannenberg C; Aschoff P; Dittmann H; Mayer F; Reischl G; von Weyhern C; Kanz L; Claussen CD; Bares R; Hartmann JT
J Nucl Med; 2010 Jun; 51(6):845-53. PubMed ID: 20484416
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
20. Variation in background intensity affects PET-based gross tumor volume delineation in non-small-cell lung cancer: the need for individualized information.
Chen GH; Yao ZF; Fan XW; Zhang YJ; Gao HQ; Qian W; Wu KL; Jiang GL
Radiother Oncol; 2013 Oct; 109(1):71-6. PubMed ID: 24060171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
